Home › Companies › Design Therapeutics, Inc. › 2025-2026
At Design Therapeutics, Inc.'s shareholder meeting held June 9, 2026, in the 2025-2026 proxy season, 51 asset managers reported how they voted on 2 ballot items in their SEC Form N-PX filings, covering 269 separate fund positions. On the most widely held item on that ballot — To elect one nominee for Class II director named herein to serve for a three-year term until… — FOR was 79% of the votes cast (FOR divided by FOR plus WITHHELD, because this ballot offered only for and withhold; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Design Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 11, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Design Therapeutics, Inc.’s Form 8-K, filed June 11, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 9, 2026: 2 items on Design Therapeutics, Inc.’s Form 8-K, filed June 11, 2026: 1 approved · 1 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2025-2026
Explore Design Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Design Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 11, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Simeon George, M.D. | 29,205,208 | -- | -- | 7,608,724 | 13,264,883 | 79% | Not verified | — |
| 2. Ratification of Selection of Independent Registered Public Accounting Firm | 50,077,708 | 201 | 906 | -- | -- | 99.9% | Approved | — |
Source: Design Therapeutics, Inc., Form 8-K, filed with the SEC on June 11, 2026 — read the filing on EDGAR.
Each item below shows how the 51 asset managers that disclosed a Design Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
Description as filed by funds: To elect one nominee for Class II director named herein to serve for a three-year term until the 2029 Annual Meeting of Stockholders: Simeon George, M.D.
Design Therapeutics, Inc.’s own tally for this item (“Elect Director: Simeon George, M.D.”): 29,205,208 for, 7,608,724 withheld, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 51 asset managers below reported 4,736,675 for, 760,419 withheld, 11 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,472,008 | 0 | 11 | 2,320 | For |
| Fidelity | 1,351,664 | 0 | 0 | 200 | For |
| BlackRock | 1,125,691 | 0 | 0 | 0 | For |
| Charles Schwab | 241,805 | 0 | 0 | 0 | For |
| Goldman Sachs | 197,799 | 0 | 0 | 0 | For |
| TIAA | 0 | 0 | 0 | 122,198 | Withhold |
| Invesco | 109,042 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 105,883 | Withhold |
| DRIEHAUS MUTUAL FUNDS | 0 | 0 | 0 | 78,741 | Withhold |
| Equitable | 42,393 | 0 | 0 | 32,210 | Mixed |
| American Century | 0 | 0 | 0 | 66,042 | Withhold |
| Nationwide | 33,928 | 0 | 0 | 19,724 | Mixed |
| ALPS ETF Trust | 0 | 0 | 0 | 50,209 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 45,000 | Withhold |
| TARGET PORTFOLIO TRUST | 41,100 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 0 | 0 | 0 | 37,964 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 36,523 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 0 | 34,990 | Withhold |
| Northern Trust | 0 | 0 | 0 | 27,448 | Withhold |
| GuideStone | 0 | 0 | 0 | 21,768 | Withhold |
| MUTUAL FUND SERIES TRUST | 0 | 0 | 0 | 21,231 | Withhold |
| Lincoln Financial | 13,300 | 0 | 0 | 1,353 | Mixed |
| Brinker Capital Destinations Trust | 581 | 0 | 0 | 13,169 | Withhold |
| Bridge Builder Trust | 11,623 | 0 | 0 | 0 | For |
| FORUM FUNDS II | 11,545 | 0 | 0 | 0 | For |
Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2026.
Design Therapeutics, Inc.’s own tally for this item (“2. Ratification of Selection of Independent Registered Public Accounting Firm”): 50,077,708 for, 201 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Ratification of Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending Dece…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 51 asset managers below reported 5,497,105 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,474,339 | 0 | 0 | 0 | For |
| Fidelity | 1,351,864 | 0 | 0 | 0 | For |
| BlackRock | 1,125,691 | 0 | 0 | 0 | For |
| Charles Schwab | 241,805 | 0 | 0 | 0 | For |
| Goldman Sachs | 197,799 | 0 | 0 | 0 | For |
| TIAA | 122,198 | 0 | 0 | 0 | For |
| Invesco | 109,042 | 0 | 0 | 0 | For |
| Dimensional | 105,883 | 0 | 0 | 0 | For |
| DRIEHAUS MUTUAL FUNDS | 78,741 | 0 | 0 | 0 | For |
| Equitable | 74,603 | 0 | 0 | 0 | For |
| American Century | 66,042 | 0 | 0 | 0 | For |
| Nationwide | 53,652 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 50,209 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 45,000 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 41,100 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 37,964 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 36,523 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 34,990 | 0 | 0 | 0 | For |
| Northern Trust | 27,448 | 0 | 0 | 0 | For |
| GuideStone | 21,768 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 21,231 | 0 | 0 | 0 | For |
| Lincoln Financial | 14,653 | 0 | 0 | 0 | For |
| Brinker Capital Destinations Trust | 13,750 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 11,623 | 0 | 0 | 0 | For |
| FORUM FUNDS II | 11,545 | 0 | 0 | 0 | For |
Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 62,456,974 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 2.36% |
| 2 | Fidelity | 2.16% |
| 3 | BlackRock | 1.80% |
| 4 | Charles Schwab | 0.39% |
| 5 | Goldman Sachs | 0.32% |
| 6 | TIAA | 0.20% |
| 7 | Invesco | 0.17% |
| 8 | Dimensional | 0.17% |
| 9 | DRIEHAUS MUTUAL FUNDS | 0.13% |
| 10 | Equitable | 0.12% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Aseem Z. Ansari, Ph.D. | 12.38% | DEF14A |
| Simeon George, M.D. | 10.58% | DEF14A |
| SR One Capital Fund I Aggregator, LP | 10.45% | 13D |
| Sirenia Capital Management LP | 9.55% | 13G |
| Light Irrevocable Trust #1 dated April 22, 2019 | 6.14% | DEF14A |
| Star Irrevocable Trust #1 dated April 22, 2019 | 6.14% | DEF14A |
| Quan Venture Fund II, L.P. | 5.42% | DEF14A |
| Point72 | 4.36% | 13F |
| Pratik Shah, Ph.D. | 4.05% | DEF14A |
| Point72 Asset Management, L.P. | 3.79% | 13G |
Percentages above are of 62,456,974 shares outstanding, as reported by Design Therapeutics, Inc. on its Form 10-Q dated April 23, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Design Therapeutics, Inc.’s 10-Q dated April 23, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Design Therapeutics, Inc. proxy season coverage: 2025-2026 (this page).
proxyvotesnow.com, “Design Therapeutics (DSGN) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/design-therapeutics-inc/2026 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.